BioSpace News Archive

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced that members of management will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, September 14 at 11:30 a.m. E.T.

Karyopharm Therapeutics Inc. announced that the Company’s senior management team will participate in the following investor conferences in September:

Rondo Therapeutics, a privately-held biotechnology company advancing next-generation immuno-oncology platforms, announces the addition of Carolyn Bertozzi, Ph.D., to its Scientific Advisory Board.

Carmell Therapeutics announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed public listing of its Class A common stock.

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the “Company”, “Evogene”), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that Ofer Haviv, Evogene’s President and CEO, will attend virtually and present at the H.C. Wainwright 24th Annual Global Investment Hybrid Conference, 2022.

GlycoMimetics, Inc. announced that Harout Semerjian, Chief Executive Officer, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY on Wednesday, September 14, 2022 at 3:00 p.m. ET.

Bristol Myers Squibb will announce results for the third quarter of 2022 on Wednesday, October 26, 2022.

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive interim data from the ongoing Phase 1b study of JK07 in heart failure with reduced ejection fraction (HFrEF).

Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SER-109 for the prevention of recurrent C. difficile infection (rCDI).